Oncogene-addicted NSCLC highlights from WCLC 2025

Medical Oncologist Dr Devika Das joined us at WCLC 2025 to share her perspectives on the latest data in oncogene-addicted non-small cell lung cancer (NSCLC). 

Watch the video update to hear Dr Das review data from the following studies: 

• Global TRUST-II: Updated efficacy and safety of taletrectinib in patients with ROS1+ NSCLC: The Global TRUST-II Study. Liu G, et al. Abstract MA02.02, WCLC 2025
• SHERLOCK: Primary endpoint results from SHERLOCK: a phase 2 trial of sotorasib, bevacizumab and chemotherapy in advanced KRAS G12C NSCLC. Lee C. K, et al. Abstract OA08.04, WCLC 2025
• REZILIENT1: Zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior amivantamab. Piotrowska Z, et al. Abstract MA08.02, WCLC 2025
• SOHO-01: Factors associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088). Le X, et al. Abstract P3.12.41, WCLC 2025
• Beamion LUNG-1: Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1. Ruiter G, et al. Abstract PT2.12.03, WCLC 2025

How will these developments impact the management of oncogene-addicted NSCLC? Watch the video update to find out, and download the accompanying slides for more detailed insights.

Clinical takeaways

• Global TRUST-II: taletrectinib demonstrated high and durable response rates, strong intracranial activity, and a favourable safety profile in both TKI-naive and TKI-pretreated ROS1+ NSCLC patients, reinforcing its potential as a next-generation ROS1 inhibitor
• SHERLOCK: first-line treatment with sotorasib plus bevacizumab and chemotherapy achieved high response rates and promising progression-free survival in KRAS G12C–mutant NSCLC across all PD-L1 groups and molecular subgroups
• REZILIENT1: zipalertinib showed meaningful efficacy and a manageable safety profile in EGFR exon 20 insertion–positive NSCLC patients who had previously received chemotherapy and amivantamab, addressing an important unmet need where no approved options currently exist
• SOHO-01: In HER2-mutant NSCLC, sevabertinib demonstrated greater efficacy in patients who had received fewer prior lines of therapy and in those with the HER2 YVMA variant, highlighting the importance of integrating clinical and molecular features to guide treatment selection
• Beamion LUNG-1: zongertinib showed both systemic and intracranial activity with durable responses in HER2-mutant NSCLC patients with brain metastases, supporting its potential as a targeted therapy for this high-risk population